Jared W Young1,2, Mark A Geyer1,2, Adam L Halberstadt1, Jordy van Enkhuizen1,3, Arpi Minassian1, Asma Khan1, William Perry1, Lisa T Eyler1,2. 1. Department of Psychiatry, University of California San Diego, California. 2. Desert-Pacific Mental Illness Research Education and Clinical Center, VA San Diego Healthcare System, San Diego, California. 3. Division of Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands.
Abstract
OBJECTIVES: Bipolar disorder (BD) is a debilitating psychiatric illness affecting 2%-5% of the population. Although mania is the cardinal feature of BD, inattention and related cognitive dysfunction are observed across all stages. Since cognitive dysfunction confers poor functional outcome in patients, understanding the relevant neural mechanisms remains key to developing novel-targeted therapeutics. METHODS: The 5-choice continuous performance test (5C-CPT) is a mouse and fMRI-compatible human attentional task, requiring responding to target stimuli while inhibiting responding to nontarget stimuli, as in clinical CPTs. This task was used to delineate systems-level neural deficits in BD contributing to inattentive performance in human subjects with BD as well as mouse models with either parietal cortex (PC) lesions or reduced dopamine transporter (DAT) expression. RESULTS: Mania BD participants exhibited severe 5C-CPT impairment. Euthymic BD patients exhibited modestly impaired 5C-CPT. High impulsivity BD subjects exhibited reduced PC activation during target and nontarget responding compared with healthy participants. In mice, bilateral PC lesions impaired both target and nontarget responding. In the DAT knockdown mouse model of BD mania, knockdown mice exhibited severely impaired 5C-CPT performance versus wildtype littermates. CONCLUSIONS: These data support the role of the PC in inattention in BD-specifically regarding identifying the appropriate response to target vs nontarget stimuli. Moreover, the findings indicate that severely reduced DAT function/hyperdopaminergia recreates the attentional deficits observed in BD mania patients. Determining the contribution of DAT in the PC to attention may provide a future target for treatment development.
OBJECTIVES: Bipolar disorder (BD) is a debilitating psychiatric illness affecting 2%-5% of the population. Although mania is the cardinal feature of BD, inattention and related cognitive dysfunction are observed across all stages. Since cognitive dysfunction confers poor functional outcome in patients, understanding the relevant neural mechanisms remains key to developing novel-targeted therapeutics. METHODS: The 5-choice continuous performance test (5C-CPT) is a mouse and fMRI-compatible human attentional task, requiring responding to target stimuli while inhibiting responding to nontarget stimuli, as in clinical CPTs. This task was used to delineate systems-level neural deficits in BD contributing to inattentive performance in human subjects with BD as well as mouse models with either parietal cortex (PC) lesions or reduced dopamine transporter (DAT) expression. RESULTS: Mania BD participants exhibited severe 5C-CPT impairment. Euthymic BD patients exhibited modestly impaired 5C-CPT. High impulsivity BD subjects exhibited reduced PC activation during target and nontarget responding compared with healthy participants. In mice, bilateral PC lesions impaired both target and nontarget responding. In the DAT knockdown mouse model of BD mania, knockdown mice exhibited severely impaired 5C-CPT performance versus wildtype littermates. CONCLUSIONS: These data support the role of the PC in inattention in BD-specifically regarding identifying the appropriate response to target vs nontarget stimuli. Moreover, the findings indicate that severely reduced DAT function/hyperdopaminergia recreates the attentional deficits observed in BD mania patients. Determining the contribution of DAT in the PC to attention may provide a future target for treatment development.
Authors: Deanna M Barch; Marc G Berman; Randy Engle; Jessica Hurdelbrink Jones; John Jonides; Angus Macdonald; Derek Evan Nee; Thomas S Redick; Scott R Sponheim Journal: Schizophr Bull Date: 2008-11-05 Impact factor: 9.306
Authors: Jordy van Enkhuizen; Dean Acheson; Victoria Risbrough; Sean Drummond; Mark A Geyer; Jared W Young Journal: Behav Brain Res Date: 2013-12-12 Impact factor: 3.332
Authors: Zackary A Cope; Adam L Halberstadt; Jordy van Enkhuizen; Aaron D Flynn; Michelle Breier; Neal R Swerdlow; Mark A Geyer; Jared W Young Journal: Psychopharmacology (Berl) Date: 2016-08-17 Impact factor: 4.530
Authors: Amy K Wagner; Xiangbai Chen; Anthony E Kline; Youming Li; Ross D Zafonte; C Edward Dixon Journal: Exp Neurol Date: 2005-10 Impact factor: 5.330
Authors: Y C Chen; W R Galpern; A L Brownell; R T Matthews; M Bogdanov; O Isacson; J R Keltner; M F Beal; B R Rosen; B G Jenkins Journal: Magn Reson Med Date: 1997-09 Impact factor: 4.668
Authors: John F Bowyer; Angela J Harris; Robert R Delongchamp; Robert L Jakab; Diane B Miller; A Roger Little; James P O'Callaghan Journal: Neurotoxicology Date: 2004-06 Impact factor: 4.294
Authors: Andrew J Grottick; David L MacQueen; Samuel A Barnes; Chris Carroll; Erin K Sanabria; Vishal Bobba; Jared W Young Journal: Psychopharmacology (Berl) Date: 2021-01-06 Impact factor: 4.530
Authors: James F Cavanagh; David Gregg; Gregory A Light; Sarah L Olguin; Richard F Sharp; Andrew W Bismark; Savita G Bhakta; Neal R Swerdlow; Jonathan L Brigman; Jared W Young Journal: Transl Psychiatry Date: 2021-09-17 Impact factor: 7.989
Authors: Nina Pocuca; Jared W Young; David A MacQueen; Scott Letendre; Robert K Heaton; Mark A Geyer; William Perry; Igor Grant; Arpi Minassian Journal: Drug Alcohol Depend Date: 2020-08-22 Impact factor: 4.492
Authors: T Jordan Walter; Nina Pocuca; Jared W Young; Mark A Geyer; Arpi Minassian; William Perry Journal: Psychiatry Res Date: 2020-12-29 Impact factor: 3.222
Authors: Molly A Kwiatkowski; Benjamin Z Roberts; Jordy van Enkhuizen; Baohu Ji; Xianjin Zhou; Jared W Young Journal: Eur Neuropsychopharmacol Date: 2020-11-13 Impact factor: 4.600